All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
ALL HubAML HubGVhD HubMDS HubMPN HubMultiple Myeloma

Tisagenlecleucel receives EC approval for the treatment of relapsed or refractory follicular lymphoma

May 6, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma/CLL

On May 4, 2022, it was announced that the European Commission (EC) had approved the use of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell product, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who previously received ≥2 lines of systemic therapy. This is the third indication tisagenlecleucel has been approved for in the EU and the first CAR T-cell therapy approved for the treatment of FL, including patients with Grade 1, 2, and 3A relapsed or refractory FL.1 The approval is based on key data obtained from the phase II ELARA trial (NCT03568461), previously reported on the Lymphoma Hub.

Of the 97 heavily pretreated patients who received tisagenlecleucel, 94 were evaluable for efficacy and 97 were evaluable for safety. The median follow-up time was approximately 21 months.


  • 86% overall response rate
  • 69% complete response rate
  • 87% of patients who achieved a complete response were still in response at ≥9 months


  • Cytokine release syndrome occurred in 50% of patients (none were Grade 3/4).
  • Neurological adverse reactions were reported in 9% of patients (1% were Grade 3/4) within 8 weeks of infusion.
  • Grade 3/4 severe infections occurred in 16% of patients.

  1. Novartis. Novartis Kymriah® receives EC approval as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphoma. Published May 5, 2022. Accessed May 5, 2022.